Related Experiment Videos
A nonplatinum combination in metastatic transitional cell carcinoma
Sandy Srinivas1, Alice E Guardino
1Stanford University Medical Center, Stanford, California, USA. sandysri@stanford.edu
American Journal of Clinical Oncology
|April 2, 2005
Summary
A combination of paclitaxel and gemcitabine chemotherapy shows significant activity and is well-tolerated in metastatic bladder cancer patients. This regimen is effective for good-risk patients unable to receive cisplatin-based treatment.
Area of Science:
- Medical Oncology
- Urothelial Carcinoma Research
- Clinical Chemotherapy Trials
Background:
- Cisplatin-based chemotherapy is the standard for metastatic bladder cancer.
- Alternative treatments are needed for patients intolerant to cisplatin or who have failed prior treatment.
Purpose of the Study:
- To evaluate the efficacy of a paclitaxel and gemcitabine combination in patients with metastatic bladder cancer who cannot receive cisplatin.
- To assess response rates and tolerability in this patient population.
Main Methods:
- Eligible patients had histologically confirmed metastatic bladder cancer with measurable disease.
- Treatment involved paclitaxel (110 mg/m2) plus gemcitabine (1000 mg/m2) every 2 weeks.
- Response was assessed via CT scans and bone scans after 2 cycles.
Main Results:
- An objective response rate of 61% was observed (13/18 patients).
- Previously treated patients achieved a 55% response rate (11/18).
- Low-risk patients showed a 100% response rate, versus 30% in intermediate-/high-risk groups (P=0.001).
Conclusions:
- The paclitaxel-gemcitabine combination is well-tolerated and active in previously treated metastatic bladder cancer.
- This regimen is a viable option for good-risk patients unsuitable for cisplatin chemotherapy.